Self-microemulsifying drug delivery system explained

A self-microemulsifying drug delivery system (SMEDDS) is a drug delivery system that uses a microemulsion achieved by chemical rather than mechanical means. That is, by an intrinsic property of the drug formulation, rather than by special mixing and handling. It employs the familiar ouzo effect displayed by anethole in many anise-flavored liquors. Microemulsions have significant potential for use in drug delivery, and SMEDDS (including so-called "U-type" microemulsions) are the best of these systems identified to date.[1] SMEDDS are of particular value in increasing the absorption of lipophilic drugs taken by mouth.

SMEDDS in research or development include formulations of the drugs anethole trithione,[2] oridonin,[3] [4] [5] curcumin,[6] vinpocetine,[7] [8] tacrolimus,[9] [10] [11] mitotane, berberine hydrochloride,[12] nobiletin,[13] piroxicam,[14] [15] anti-malaria drugs beta-artemether[16] and halofantrine,[17] anti-HIV drug UC 781,[18] [19] nimodipine,[20] [21] exemestane,[22] anti-cancer drugs 9-nitrocamptothecin (9-NC)[23] paclitaxel,[24] [25] and seocalcitol,[26] [27] alprostadil (intraurethral use),[28] probucol,[29] [30] itraconazole,[31] fenofibrate,[32] acyclovir,[33] simvastatin,[34] [35] xibornol,[36] silymarin,[37] [38] alpha-asarone,[39] enilconazole,[18] puerarin (an isoflavone found in Pueraria lobata),[40] [41] [42] [43] atorvastatin,[44] [45] [46] heparin,[47] carvedilol,[48] ketoconazole,[49] gentamicin,[50] labrasol,[51] flurbiprofen,[52] celecoxib,[53] danazol,[54] cyclosporine,[55] and idebenone.[56]

Actual applications of Self-microemulsifying drug delivery system (SMEDDS) remain rare. The first drug marketed as a SMEDDS was cyclosporin, and it had significantly improved bioavailability compared with the conventional solution. In the last decade, several SMEDDS loaded with antiviral drugs (ritonavir, saquinavir) were tested for treatment of HIV infection, but the relative improvement in clinical benefit was not significant. The SMEDDS formulation of ritonavir (soft capsules) has been withdrawn in some countries.[57]

Within the last years SMEDDS were also utilized for the oral administration of biologics. Due to ion pairing with appropriate surfactants [58] these mainly hydrophilic macromolecular drugs can be incorporated in the lipophilic phase of SMEDDS. Provided that the oily droplets being formed in the gut are sufficiently stable towards lipases,[59] can permeate the mucus gel layer in sufficient quantities [60] and exhibit permeation enhancing properties [61] the oral bioavailability of various biologics can be strongly improved [62]

SMEDDS offer numerous advantages: spontaneous formation, ease of manufacture, thermodynamic stability, and improved solubilization of bioactive materials.[1] Improved solubility contributes to faster release rates and greater bioavailability. For many drugs taken by mouth, faster release rates improve the drug acceptance by consumers. Greater bioavailability means that less drug need be used; this may lower cost, and does lower the stomach irritation and toxicity of drugs taken by mouth.

For oral use, SMEDDS may be formulated as liquids or solids, the solids packaged in capsules or tablets. Limited studies comparing these report that in terms of bioavailability liquid SMEDDS are superior to solid SMEDDS,[20] which are superior to conventional tablets.[20] [42] [47] Liquid SMEDDS have also shown value in injectable (IV and urethral) formulations and in a topical (oral) spray.[36]

See also

Further reading

Notes and References

  1. Spernath A . Aserin A . Microemulsions as carriers for drugs and nutraceuticals. Adv Colloid Interface Sci. 128-130. 47–64. December 2006. 17229398. 10.1016/j.cis.2006.11.016.
  2. Jing Q . Shen Y . Ren F . Chen J . Jiang Z . Peng B . Leng Y . Dong J . HPLC determination of anethole trithione and its application to pharmacokinetics in rabbits. J Pharm Biomed Anal. 42. 5. 613–7. November 2006. 16824723. 10.1016/j.jpba.2006.05.013.
  3. Zhang P . Liu Y . Feng N . Xu J . Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm. 355. 1–2. 269–76. May 2008. 18242895. 10.1016/j.ijpharm.2007.12.026.
  4. Liu Y . Zhang P . Feng NP . Zhang X . Xu J . [Release kinetics of oridonin self-microemulsifying drug delivery system in vitro]. zh. Zhongguo Zhong Yao Za Zhi. 33. 18. 2049–52. September 2008. 19160780.
  5. Liu Y . Zhang P . Feng N . Zhang X . Wu S . Zhao J . Optimization and in situ intestinal absorption of self-microemulsifying drug delivery system of oridonin. Int J Pharm. 365. 1–2. 136–42. January 2009. 18782611. 10.1016/j.ijpharm.2008.08.009.
  6. Cui J . Yu B . Zhao Y . Zhu W . Li H . Lou H . Zhai G . Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm. 371. 1–2. 148–55. December 2008. 19124065. 10.1016/j.ijpharm.2008.12.009.
  7. Chen Y . Li G . Wu X . Chen Z . Hang J . Qin B . Chen S . Wang R . Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine: formulation development and in vivo assessment. Biol. Pharm. Bull.. 31. 1. 118–25. January 2008. 18175953. 10.1248/bpb.31.118. free.
  8. Cui SX . Nie SF . Li L . Wang CG . Pan WS . Sun JP . Preparation and Evaluation of Self-Microemulsifying Drug Delivery System Containing Vinpocetine. Drug Dev Ind Pharm. 35. 5. 603–611. November 2008. 19040178. 10.1080/03639040802488089.
  9. Borhade VB . Nair HA . Hegde DD . Development and Characterization of Self-Microemulsifying Drug Delivery System of Tacrolimus for Intravenous Administration. Drug Dev Ind Pharm. 35. 5. 619–630. October 2008. 18979309. 10.1080/03639040802498856. 7127624 .
  10. Borhade V . Nair H . Hegde D . Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS PharmSciTech. 9. 1. 13–21. 2008. 18446456. 10.1208/s12249-007-9014-8. 2976874.
  11. Borhade VB . Nair HA . Hegde DD . Barhate CR . Development and Validation of HPTLC Method for Estimation of Tacrolimus in Formulations. Drug Dev Ind Pharm. 35. 4. 440–448. November 2008. 19040177. 10.1080/03639040802430594. 97608266 .
  12. Zhang BE . Lu WB . Chen WW . [Study on self-microemulsifying drug delivery system of Jiaotai Pill active components]. zh. Zhong Yao Cai. 31. 7. 1068–71. July 2008. 18973026.
  13. Yao J . Lu Y . Zhou JP . Preparation of nobiletin in self-microemulsifying systems and its intestinal permeability in rats . J Pharm Pharm Sci . 11 . 3 . 22–9 . 2008 . 18801304 . 10.18433/J3MS3M . 2009-03-13 . https://web.archive.org/web/20110706210853/http://ejournals.library.ualberta.ca/index.php/JPPS/article/viewFile/1462/1639 . 2011-07-06 . live. free .
  14. Attama AA . Nkemnele MO . In vitro evaluation of drug release from self micro-emulsifying drug delivery systems using a biodegradable homolipid from Capra hircus. Int J Pharm. 304. 1–2. 4–10. November 2005. 16198521. 10.1016/j.ijpharm.2005.08.018.
  15. Zhou XT . Wang J . Wang Y . Sun JY . Nie SF . Pan WS . [Design and in vitro evaluation of self-microemulsifying drug delivery systems for piroxicam]. zh. Yao Xue Xue Bao. 43. 4. 415–20. April 2008. 18664206.
  16. Mandawgade SD . Sharma S . Pathak S . Patravale VB . Development of SMEDDS using natural lipophile: application to beta-Artemether delivery. Int J Pharm. 362. 1–2. 179–83. October 2008. 18652886. 10.1016/j.ijpharm.2008.06.021.
  17. Holm R . Porter CJ . Edwards GA . Müllertz A . Kristensen HG . Charman WN . Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides . Eur J Pharm Sci . 20 . 1 . 91–7 . September 2003 . 13678797 . 10.1016/S0928-0987(03)00174-X.
  18. Goddeeris C . Coacci J . Van den Mooter G . Correlation between digestion of the lipid phase of smedds and release of the anti-HIV drug UC 781 and the anti-mycotic drug enilconazole from smedds. Eur J Pharm Biopharm. 66. 2. 173–81. May 2007. 17158039. 10.1016/j.ejpb.2006.10.005.
  19. Goddeeris C . Van den Mooter G . Free flowing solid dispersions of the anti-HIV drug UC 781 with Poloxamer 407 and a maximum amount of TPGS 1000: investigating the relationship between physicochemical characteristics and dissolution behaviour. Eur J Pharm Sci. 35. 1–2. 104–13. September 2008. 18644442. 10.1016/j.ejps.2008.06.010.
  20. Yi T . Wan J . Xu H . Yang X . A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs. Eur J Pharm Biopharm. 70. 2. 439–44. October 2008. 18603415. 10.1016/j.ejpb.2008.05.001.
  21. Yi T . Wan J . Xu H . Yang X . Controlled poorly soluble drug release from solid self-microemulsifying formulations with high viscosity hydroxypropylmethylcellulose. Eur J Pharm Sci. 34. 4–5. 274–80. August 2008. 18541418. 10.1016/j.ejps.2008.04.010. free.
  22. Singh AK . Chaurasiya A . Singh M . Upadhyay SC . Mukherjee R . Khar RK . Exemestane loaded self-microemulsifying drug delivery system (SMEDDS): development and optimization. AAPS PharmSciTech. 9. 2. 628–34. 2008. 18473177. 10.1208/s12249-008-9080-6. 2976939.
  23. Lu JL . Wang JC . Zhao SX . Liu XY . Zhao H . Zhang X . Zhou SF . Zhang Q . Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. Eur J Pharm Biopharm. 69. 3. 899–907. August 2008. 18434109. 10.1016/j.ejpb.2008.02.023.
  24. Yang S . Gursoy RN . Lambert G . Benita S . Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm. Res.. 21. 2. 261–70. February 2004. 15032307. 10.1023/B:PHAM.0000016238.44452.f1. 24590025 .
  25. Kang BK . Chon SK . Kim SH . Jeong SY . Kim MS . Cho SH . Lee HB . Khang G . Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo. Int J Pharm. 286. 1–2. 147–56. November 2004. 15501011. 10.1016/j.ijpharm.2004.08.008.
  26. Grove M . Müllertz A . Nielsen JL . Pedersen GP . Bioavailability of seocalcitol II: development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Eur J Pharm Sci. 28. 3. 233–42. June 2006. 16650738. 10.1016/j.ejps.2006.02.005.
  27. Grove M . Müllertz A . Pedersen GP . Nielsen JL . Bioavailability of seocalcitol III. Administration of lipid-based formulations to minipigs in the fasted and fed state. Eur J Pharm Sci. 31. 1. 8–15. May 2007. 17383165. 10.1016/j.ejps.2007.01.007.
  28. Lee S . Lee J . Choi YW . Design and evaluation of prostaglandin E1 (PGE1) intraurethral liquid formulation employing self-microemulsifying drug delivery system (SMEDDS) for erectile dysfunction treatment. Biol. Pharm. Bull.. 31. 4. 668–72. April 2008. 18379060. 10.1248/bpb.31.668. free.
  29. Ljusberg-Wahren H . Seier Nielsen F . Brogård M . Troedsson E . Müllertz A . Enzymatic characterization of lipid-based drug delivery systems. Int J Pharm. 298. 2. 328–32. July 2005. 15979260. 10.1016/j.ijpharm.2005.02.038.
  30. Fatouros DG . Nielsen FS . Douroumis D . Hadjileontiadis LJ . Mullertz A . In vitro-in vivo correlations of self-emulsifying drug delivery systems combining the dynamic lipolysis model and neuro-fuzzy networks. Eur J Pharm Biopharm. 69. 3. 887–98. August 2008. 18367386. 10.1016/j.ejpb.2008.01.022.
  31. Woo JS . Song YK . Hong JY . Lim SJ . Kim CK . Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. Eur J Pharm Sci. 33. 2. 159–65. February 2008. 18178070. 10.1016/j.ejps.2007.11.001.
  32. Patel AR . Vavia PR . Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J. 9. 3. E344–52. 2007. 18170981. 10.1208/aapsj0903041. 2751486 .
  33. Patel D . Sawant KK . Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS). Drug Dev Ind Pharm. 33. 12. 1318–26. December 2007. 18097805. 10.1080/03639040701385527. 3119405 .
  34. Kang BK . Lee JS . Chon SK . Jeong SY . Yuk SH . Khang G . Lee HB . Cho SH . Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm. 274. 1–2. 65–73. April 2004. 15072783. 10.1016/j.ijpharm.2003.12.028.
  35. Meng J . Zheng L . Application of mixture experimental design to simvastatin apparent solubility predictions in the microemulsifion formed by self-microemulsifying. Drug Dev Ind Pharm. 33. 9. 927–31. September 2007. 17891578. 10.1080/03639040601003733. 37334831 .
  36. Cirri M . Mura P . Mora PC . Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems. Int J Pharm. 340. 1–2. 84–91. August 2007. 17531411. 10.1016/j.ijpharm.2007.03.021.
  37. Wu W . Wang Y . Que L . Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm. 63. 3. 288–94. July 2006. 16527467. 10.1016/j.ejpb.2005.12.005.
  38. Woo JS . Kim TS . Park JH . Chi SC . Formulation and biopharmaceutical evaluation of silymarin using SMEDDS. Arch. Pharm. Res.. 30. 1. 82–9. January 2007. 17328246. 10.1007/BF02977782. 22169992 .
  39. Wang DK . Shi ZH . Liu L . Wang XY . Zhang CX . Zhao P . Development of self-microemulsifying drug delivery systems for oral bioavailability enhancement of alpha-Asarone in beagle dogs. PDA J Pharm Sci Technol. 60. 6. 343–9. 2006. 17260899.
  40. Cui S . Zhao C . Chen D . He Z . Self-microemulsifying drug delivery systems (SMEDDS) for improving in vitro dissolution and oral absorption of Pueraria lobata isoflavone. Drug Dev Ind Pharm. 31. 4–5. 349–56. May 2005. 16093200. 10.1081/DDC-54309. 9408964 .
  41. Cui S . Zhao C . Tang X . Chen D . He Z . Study on the bioavailability of puerarin from Pueraria lobata isoflavone self-microemulsifying drug-delivery systems and tablets in rabbits by liquid chromatography-mass spectrometry. Biomed. Chromatogr.. 19. 5. 375–8. June 2005. 15627278. 10.1002/bmc.460.
  42. Yu AH . Zhai GX . Cui J . Liu H . [Preparation of puerarin solid self-microemulsion]. zh. Zhong Yao Cai. 29. 8. 834–8. August 2006. 17076244.
  43. Cui SM . Zhao CS . He ZG . [Assessment of Pueraria lobata isoflavone with self-microemulsifying drug delivery systems in vitro and in vivo]. zh. Zhong Yao Cai. 30. 6. 684–7. June 2007. 17918441.
  44. Shen HR . Li ZD . Zhong MK . [Preparation and evaluation of self-microemulsifying drug delivery systems containing atorvastatin]. zh. Yao Xue Xue Bao. 40. 11. 982–7. November 2005. 16499080.
  45. Shen HR . Li ZD . Zhong MK . HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system. Pharmazie. 61. 1. 18–20. January 2006. 16454200.
  46. Shen H . Zhong M . Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J. Pharm. Pharmacol.. 58. 9. 1183–91. September 2006. 16945176. 10.1211/jpp.58.9.0004. 22542504 .
  47. Ito Y . Kusawake T . Prasad YV . Sugioka N . Shibata N . Takada K . Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. Int J Pharm. 317. 2. 114–9. July 2006. 16631328. 10.1016/j.ijpharm.2006.02.056.
  48. Wei L . Sun P . Nie S . Pan W . Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Dev Ind Pharm. 31. 8. 785–94. September 2005. 16221613. 10.1080/03639040500216428. 12794172 .
  49. Heo MY . Piao ZZ . Kim TW . Cao QR . Kim A . Lee BJ . Effect of solubilizing and microemulsifying excipients in polyethylene glycol 6000 solid dispersion on enhanced dissolution and bioavailability of ketoconazole. Arch. Pharm. Res.. 28. 5. 604–11. May 2005. 15974450. 10.1007/BF02977766. 11978203 .
  50. Ito Y . Kusawake T . Ishida M . Tawa R . Shibata N . Takada K . Oral solid gentamicin preparation using emulsifier and adsorbent. J Control Release. 105. 1–2. 23–31. June 2005. 15908031. 10.1016/j.jconrel.2005.03.017.
  51. Sha X . Yan G . Wu Y . Li J . Fang X . Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci. 24. 5. 477–86. April 2005. 15784337. 10.1016/j.ejps.2005.01.001.
  52. Li P . Ghosh A . Wagner RF . Krill S . Joshi YM . Serajuddin AT . Effect of combined use of nonionic surfactant on formation of oil-in-water microemulsions. Int J Pharm. 288. 1. 27–34. January 2005. 15607255. 10.1016/j.ijpharm.2004.08.024.
  53. Subramanian N . Ray S . Ghosal SK . Bhadra R . Moulik SP . Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol. Pharm. Bull.. 27. 12. 1993–9. December 2004. 15577219. 10.1248/bpb.27.1993. free.
  54. Porter CJ . Kaukonen AM . Boyd BJ . Edwards GA . Charman WN . Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm. Res.. 21. 8. 1405–12. August 2004. 15359575. 10.1023/B:PHAM.0000036914.22132.cc. 8763220 .
  55. Postolache P . Petrescu O . Dorneanu V . Zanini AC . Cyclosporine bioavailability of two physically different oral formulations. Eur Rev Med Pharmacol Sci. 6. 6. 127–31. 2002. 12776806.
  56. Kim HJ . Yoon KA . Hahn M . Park ES . Chi SC . Preparation and in vitro evaluation of self-microemulsifying drug delivery systems containing idebenone. Drug Dev Ind Pharm. 26. 5. 523–9. May 2000. 10789064. 10.1081/DDC-100101263. 32771754 .
  57. Gibaud . S. P. . Attivi . D. . 10.1517/17425247.2012.694865 . Microemulsions for oral administration and their therapeutic applications . Expert Opinion on Drug Delivery . 937–951. 2012 . 22663249. 9. 8 . 28468973 .
  58. Zupančič. O. Partenhauser . A. Lam. H Th. Rohrer. J. Bernkop-Schnürch. A. Development and in vitro characterisation of an oral self-emulsifying delivery system for daptomycin. European Journal of Pharmaceutical Sciences. 2016. 81. 129–136. 10.1016/j.ejps.2015.10.005. 26485536.
  59. Leonaviciute. G. Bernkop-Schnürch. A. Self-emulsifying drug delivery systems in oral (poly)peptide drug delivery. Expert Opin Drug Deliv . 2015. 12. 11. 1703–1716. 10.1517/17425247.2015.1068287. 26477549. 21890042.
  60. Friedl. H. Dünnhaupt. S. Hintzen. F. Waldner. C. Parikh. S. Pearson. JP. Wilcox. MD. Bernkop-Schnürch. A. Development and evaluation of a novel mucus diffusion test system approved by self-nanoemulsifying drug delivery systems.. J Pharm Sci. 2013. 102. 12. 4406–4413. 10.1002/jps.23757. 24258284.
  61. Sha. X. Yan. G. Wu. Y. Li. J. Fang. X. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells.. Eur J Pharm Sci. 2005. 24. 5. 477–486. 10.1016/j.ejps.2005.01.001. 15784337.
  62. Hintzen . F. Perera. G. Hauptstein. S. Müller. C. Laffleur. F. Bernkop-Schnürch. A. In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin . Int J Pharm. 2014. 472. 1–2. 20–26. 10.1016/j.ijpharm.2014.05.047. 24879935.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Self-microemulsifying drug delivery system".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.